1-Oxido-1,2-dihydroquinolin-1-ium

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-Oxido-1,2-dihydroquinolin-1-ium
• 化学式: C9H9NO
• 分子量: 147.17
• InChiKey: IIMTUMREOUTRIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  21.5
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE POUR LE TRAITEMENT DU CANCER
  申请人：GENENTECH INC

  公开号：WO2017205538A1

  公开（公告）日：2017-11-30

  The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders such as cancer, inflammatory disorders and autoimmune diseases.

  本发明涉及一种化合物公式（I）及其盐，其中R1、R2X和Y具有本文中定义的任何值，以及其组合物和用途。这些化合物可用作CBP和/或EP300的抑制剂。还包括包含公式（I）化合物或其药学上可接受的盐的药物组合物，以及在治疗各种CBP和/或EP300介导的疾病，如癌症、炎症性疾病和自身免疫疾病中使用这些化合物和盐的方法。
• Fused thiophone derivatives and drugs containing the same as the active ingredient
  申请人：——

  公开号：US20030073706A1

  公开（公告）日：2003-04-17

  The present invention relates to a fused thiophene derivative of the formula (I) (wherein all the symbols are defined as described in the specification) and an inhibitor of producing interleukin-6 and/or interleukin-12 comprising the said derivative as an active ingredient. A fused thiophene derivative of the formula (I) is useful as an agent for the prevention and/or treatment of various inflammatory diseases, sepsis, multiple myeloma, plasma cell leukemia, osteoporosis, cachexia, psoriasis, nephritis, renal cell carcinoma, Kaposi's sarcoma, rheumatoid arthritis, gammopathy, Castleman's disease, atrial myxoma, diabetes mellitus, autoimmune diseases, hepatitis, multiple sclerosis, colitis, graft versus host immune diseases, infectious diseases. 1

  本发明涉及公式（I）的融合噻吩衍生物（其中所有符号如规范中所述）和一种抑制产生白细胞介素-6和/或白细胞介素-12的抑制剂，其包含所述衍生物作为活性成分。公式（I）的融合噻吩衍生物可用作预防和/或治疗各种炎症性疾病、败血症、多发性骨髓瘤、浆细胞白血病、骨质疏松症、消瘦症、银屑病、肾炎、肾细胞癌、卡波西肉瘤、类风湿性关节炎、免疫球蛋白病、卡斯特曼病、心房黏液瘤、糖尿病、自身免疫疾病、肝炎、多发性硬化症、结肠炎、移植物抗宿主免疫疾病、传染病的药剂。
• FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1067128A1

  公开（公告）日：2001-01-10

  Fused thiophene derivatives represented by general formula (I) and interleukin-6 and/or interleukin-12 production inhibitors containing these derivatives as the active ingredient (in general formula (I), each symbol has the meaning as defined in the specification). The fused thiophene derivatives represented by general formula (I) are useful as preventives and/or remedies for various inflammatory diseases, sepsis, multiple myeloma, plasma cell leukemia, osteoporosis, cachexia, psoriasis, nephritis, renal cell cancer, Kaposi's sarcoma, chronic rheumatoid arthritis, hypergamma-globulinemia, Curschmann's disease, intraartial myxoma, diabetes, autoimmune diseases, hepatitis, multiple sclerosis, colon inflammation, graft-versus-host disease and infectious diseases.

  通式(I)代表的融合噻吩衍生物和含有这些衍生物作为活性成分的白细胞介素-6和/或白细胞介素-12产生抑制剂（在通式(I)中，每个符号的含义如说明书中所定义）。通式（I）所代表的融合噻吩衍生物可作为各种炎症、败血症、多发性骨髓瘤、浆细胞白血病、骨质疏松症、恶病质、牛皮癣、肾炎、肾细胞癌的预防和/或治疗药物、卡波西肉瘤、慢性类风湿性关节炎、高丙种球蛋白血症、库希曼病、关节内肌瘤、糖尿病、自身免疫性疾病、肝炎、多发性硬化症、结肠炎、移植物抗宿主病和传染病。
• LACTAM COMPOUND DERIVATIVE AND APPLICATION THEREOF
  申请人：NHWA Pharma Corporation

  公开号：EP3381915A1

  公开（公告）日：2018-10-03

  The present invention relates to a lactam compound derivative, a medicine composition comprising the lactam compound derivative, and uses of the composition and the lactam compound derivative in preparation of a medicine for preventing or treating schizophrenia, the lactam compound derivative having a structure as shown in Formula I.

  本发明涉及一种内酰胺化合物衍生物、一种包含该内酰胺化合物衍生物的药物组合物，以及该组合物和内酰胺化合物衍生物在制备预防或治疗精神分裂症的药物中的用途，该内酰胺化合物衍生物具有如式 I 所示的结构。
• HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR
  申请人：ZENECA LIMITED

  公开号：EP0971895A1

  公开（公告）日：2000-01-19